<SEC-DOCUMENT>0000950170-25-009227.txt : 20250127
<SEC-HEADER>0000950170-25-009227.hdr.sgml : 20250127
<ACCEPTANCE-DATETIME>20250127163009
ACCESSION NUMBER:		0000950170-25-009227
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20250127
ITEM INFORMATION:		Submission of Matters to a Vote of Security Holders
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250127
DATE AS OF CHANGE:		20250127

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lineage Cell Therapeutics, Inc.
		CENTRAL INDEX KEY:			0000876343
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				943127919
		STATE OF INCORPORATION:			CA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12830
		FILM NUMBER:		25559432

	BUSINESS ADDRESS:	
		STREET 1:		2173 SALK AVENUE
		STREET 2:		SUITE 200
		CITY:			CARLSBAD
		STATE:			CA
		ZIP:			92008
		BUSINESS PHONE:		5105213390

	MAIL ADDRESS:	
		STREET 1:		2173 SALK AVENUE
		STREET 2:		SUITE 200
		CITY:			CARLSBAD
		STATE:			CA
		ZIP:			92008

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOTIME INC
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>lctx-20250127.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-01-27T12:54:15.8111+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:lctx="http://lineagecell.com/20250127" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_00731e60-6969-45d2-b21c-f9c8515ca503" name="dei:AmendmentFlag" contextRef="C_000a1c80-a808-446b-84e2-9057827f4e98">false</ix:nonNumeric><ix:nonNumeric id="F_1511b0e0-be9d-4105-98a8-ce8a53903ae1" name="dei:EntityCentralIndexKey" contextRef="C_000a1c80-a808-446b-84e2-9057827f4e98">0000876343</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="lctx-20250127.xsd"/></ix:references><ix:resources><xbrli:context id="C_000a1c80-a808-446b-84e2-9057827f4e98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000876343</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-27</xbrli:startDate><xbrli:endDate>2025-01-27</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="border-top:2.25pt double #000000;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES<br/>SECURITIES AND EXCHANGE COMMISSION<br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e2cdc7d0-99d8-4e41-9246-0cf306c0a534" contextRef="C_000a1c80-a808-446b-84e2-9057827f4e98" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CURRENT REPORT</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.02986111111111111in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span><ix:nonNumeric id="F_c1d3fc7a-01a1-4e51-9885-3376d7852ec9" contextRef="C_000a1c80-a808-446b-84e2-9057827f4e98" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">January 27, 2025</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="margin-left:40%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bdd069ce-eb00-478d-b110-0c0e4c42da11" contextRef="C_000a1c80-a808-446b-84e2-9057827f4e98" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lineage Cell Therapeutics, Inc.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:20%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:20%;box-sizing:content-box;"/>
    <td style="width:18%;box-sizing:content-box;"/>
    <td style="width:41%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_42546a62-bb9c-47a9-99aa-d569989f5ace" contextRef="C_000a1c80-a808-446b-84e2-9057827f4e98" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">California</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_dd646a90-5184-4142-9928-165003f79cc8" contextRef="C_000a1c80-a808-446b-84e2-9057827f4e98" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">001-12830</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_a815a7da-502d-48bd-a888-5848518fbdc3" contextRef="C_000a1c80-a808-446b-84e2-9057827f4e98" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">94-3127919</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(State or Other Jurisdiction<br/>of Incorporation)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Commission File Number)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(IRS Employer<br/>Identification No.)</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_a089bc55-c72e-4a72-aac7-3bdc9b83205d" contextRef="C_000a1c80-a808-446b-84e2-9057827f4e98" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2173 Salk Avenue, Suite 200</span></ix:nonNumeric></span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_9d08df4b-be4d-43f5-90df-ee15c895dc87" contextRef="C_000a1c80-a808-446b-84e2-9057827f4e98" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Carlsbad</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_83451471-53d6-4b35-931c-8dbe992ebdcc" contextRef="C_000a1c80-a808-446b-84e2-9057827f4e98" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">California</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_baa5bd89-0faf-4e0f-af32-0a286589fe51" contextRef="C_000a1c80-a808-446b-84e2-9057827f4e98" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">92008</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.125in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.02986111111111111in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Registrant&#8217;s Telephone Number, Including Area Code:</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_e2bd2a59-dc1e-49b2-a21a-848302ddbd56" contextRef="C_000a1c80-a808-446b-84e2-9057827f4e98" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(442)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_037f4153-962b-42bf-8351-395e61f76bcc" contextRef="C_000a1c80-a808-446b-84e2-9057827f4e98" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">287-8990</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"/>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.125in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:9pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_be7233e3-48e6-4e96-b30d-888c6f33106c" contextRef="C_000a1c80-a808-446b-84e2-9057827f4e98" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_05a5f538-fb19-4d4f-ac6f-3a3523ab6cd4" contextRef="C_000a1c80-a808-446b-84e2-9057827f4e98" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e48a216c-bb7d-4302-a72e-92b84f7297f9" contextRef="C_000a1c80-a808-446b-84e2-9057827f4e98" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f9867ecd-1cda-4a7a-b8a0-099a79a0be9d" contextRef="C_000a1c80-a808-446b-84e2-9057827f4e98" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:9pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:15%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:45%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>Title of each class</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading<br/>Symbol(s)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_809a53cb-dcef-40d9-83ee-6a394a975b8b" contextRef="C_000a1c80-a808-446b-84e2-9057827f4e98" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common shares</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_371a4c04-2b21-481e-93bc-e0feb11499ba" contextRef="C_000a1c80-a808-446b-84e2-9057827f4e98" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">LCTX</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_b2dba600-ad30-4ffa-83da-2b8001ce5898" contextRef="C_000a1c80-a808-446b-84e2-9057827f4e98" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">NYSE American LLC</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Emerging growth company </span><span style="font-size:10pt;"><ix:nonNumeric id="F_61e8b6f9-827d-4d25-bdbc-7d6341a1c7c1" contextRef="C_000a1c80-a808-446b-84e2-9057827f4e98" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 5.07 Submission of Matters to a Vote of Security Holders.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 27, 2025, Lineage Cell Therapeutics, Inc. (the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;), held a special meeting of shareholders. The matters voted upon at the meeting are described in detail in our definitive proxy statement for the meeting, filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on December 9, 2024. Below is a brief description of each such matter and the final voting results, including the number of votes cast for, withheld or against, the number of abstentions and the number of broker non-votes with respect to each matter, as applicable. Voting results are, when applicable, reported by rounding fractional share voting down to the nearest whole number.</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Shareholders approved, for purposes of complying with NYSE American LLC listing standards and requirements, the issuance of our common shares and common warrants pursuant to the terms of the securities purchase agreement, dated November 19, 2024, between us and Broadwood Partners, L.P., and our common shares issuable upon exercise of such common warrants. </span></div></div>
  <table style="margin-left:6.13%;border-spacing:0;table-layout:auto;width:94.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:23.655%;box-sizing:content-box;"/>
    <td style="width:2.16%;box-sizing:content-box;"/>
    <td style="width:23.655%;box-sizing:content-box;"/>
    <td style="width:2.16%;box-sizing:content-box;"/>
    <td style="width:22.575%;box-sizing:content-box;"/>
    <td style="width:3.219%;box-sizing:content-box;"/>
    <td style="width:21.496%;box-sizing:content-box;"/>
    <td style="width:1.08%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:11.85pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Votes For</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Votes Against</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Abstentions</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Broker Non-Votes</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10.8pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="border-top:1pt solid #000000;padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114,132,309</span></p></td>
    <td style="border-top:1pt solid #ffffff03;padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="border-top:1pt solid #000000;padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,732,082</span></p></td>
    <td style="border-top:1pt solid #ffffff03;padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="border-top:1pt solid #000000;padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">362,083</span></p></td>
    <td style="border-top:1pt solid #ffffff03;padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="border-top:1pt solid #000000;padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span></p></td>
    <td style="border-top:1pt solid #ffffff03;padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Shareholders approved the adjournment of the meeting, if necessary or advisable, to solicit additional proxies in favor of proposal 1 if there were not sufficient votes to approve such proposal at the time of the meeting or any adjournment or postponement thereof.</span></div></div>
  <table style="margin-left:6.13%;border-spacing:0;table-layout:auto;width:94.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:23.66%;box-sizing:content-box;"/>
    <td style="width:2.14%;box-sizing:content-box;"/>
    <td style="width:23.66%;box-sizing:content-box;"/>
    <td style="width:2.16%;box-sizing:content-box;"/>
    <td style="width:22.58%;box-sizing:content-box;"/>
    <td style="width:3.22%;box-sizing:content-box;"/>
    <td style="width:21.5%;box-sizing:content-box;"/>
    <td style="width:1.08%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:11.85pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Votes For</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Votes Against</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Abstentions</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Broker Non-Votes</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10.8pt;background-color:#cceeff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="border-top:1pt solid #000000;padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">112,392,014</span></p></td>
    <td style="border-top:1pt solid #ffffff03;padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="border-top:1pt solid #000000;padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,458,712</span></p></td>
    <td style="border-top:1pt solid #ffffff03;padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="border-top:1pt solid #000000;padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">375,748</span></p></td>
    <td style="border-top:1pt solid #ffffff03;padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="border-top:1pt solid #000000;padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0</span></p></td>
    <td style="border-top:1pt solid #ffffff03;padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 7.01 Regulation FD Disclosure.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 27, 2025, we issued a press release announcing the closing of the offering described in Item 8.01 of this report, a copy of which is furnished as Exhibit 99.1 hereto.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information in this Item 7.01 and in the press release furnished as Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and is not incorporated by reference into any of our filings under the Securities Act or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 8.01 Other Events.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following receipt of stockholder approval of proposal 1 described in Item 5.07 of this report, we closed the second tranche of the registered direct offering announced on November 20, 2024. In connection with such closing, we issued 7,894,737 common shares and an accompanying warrant to purchase an aggregate of up to 7,894,737 common shares, at a combined purchase price of $0.76 per common share and accompanying warrant, to Broadwood Partners, L.P., an affiliate of Neal Bradsher, a member of our board of directors. Such warrant will be exercisable for one common share at an exercise price of $0.91 per common share commencing on May 21, 2025 and will expire on the earlier of (a) May 21, 2028, and (b) the 90th day following the date of the public disclosure of the intent to advance OpRegen&#174; (also known as RG6501) into a multi-center phase 2 or 3 clinical trial which includes a control or comparator arm, or if the date of such public disclosure occurs prior to May 21, 2025, the 90th day following May 21, 2025. The foregoing description of the warrant does not purport to be complete and is qualified in its entirety by the full text thereof, a copy of which is attached as an exhibit 4.1 to this report and incorporated by reference herein.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We received $6 million in gross proceeds at the closing, before deducting placement agent&#8217;s fees and other offering expenses payable by us. We received $24 million in gross proceeds at the first closing of the offering in November 2024 and may receive up to an additional $36 million of gross proceeds upon the exercise in full on a cash basis of the warrants issued in the offering. No assurance can be given that any of the warrants issued in the offering will be exercised on a cash basis, or at all. We currently plan to use the net proceeds from the offering for working capital and general corporate purposes, including research and development expenses and capital expenditures.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also issued warrants to H.C. Wainwright &amp; Co., who acted as the exclusive placement agent for the offering, or its designees to purchase an aggregate of up to 394,736 common shares. Such warrants have substantially the same terms as the warrant described above, except they have an exercise price of $0.95 per common share.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The securities described above were offered and sold by Lineage in a registered direct offering pursuant to a &#8220;shelf&#8221; registration statement on Form S-3 (File No. 333-277758) filed with the SEC on March 7, 2024, and which was declared effective by the SEC on May 14, 2024. The offering of the securities in the registered direct offering was made only by means of a base prospectus and a prospectus supplement that forms a part of the effective registration statement. A final prospectus supplement and the accompanying base prospectus relating to the offering were filed with the SEC and are available on the SEC&#8217;s website at www.sec.gov.</span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(d) Exhibits.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:8.08%;box-sizing:content-box;"/>
    <td style="width:1.02%;box-sizing:content-box;"/>
    <td style="width:90.9%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit No.</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrant issued to Broadwood Partners, L.P. on January 27, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.1</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Press release issued on January 27, 2025</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
  <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:6%;box-sizing:content-box;"/>
    <td style="width:42%;box-sizing:content-box;"/>
    <td style="width:6%;box-sizing:content-box;"/>
    <td style="width:46%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:4.3pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lineage Cell Therapeutics, Inc.</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 27, 2025</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ George A. Samuel III</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Title:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">George A. Samuel III<br/>General Counsel and Corporate Secretary</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>lctx-ex4_1.htm
<DESCRIPTION>EX-4.1
<TEXT>
<html>
 <head>
  <title>EX-4.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">COMMON SHARE PURCHASE WARRANT</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lineage Cell Therapeutics, Inc.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrant Shares: 7,894,737					Issue Date: January 27, 2025</font></p>
  <p style="margin-left:46.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">THIS COMMON SHARE PURCHASE WARRANT (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) certifies that, for value received, Broadwood Partners L.P. or its assigns (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Holder</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) is entitled, upon the terms and conditions hereinafter set forth, at any time on or after May 21, 2025 (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Initial Exercise Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) and on or prior to 5:00 p.m. (New York City time) on the earlier of (i) the three (3) year anniversary of the Initial Exercise Date, and (ii) the 90th day following the date of the public disclosure of the occurrence of the Milestone Event, subject to the satisfaction of the Equity Conditions (as defined below) or if the date of the public disclosure of the occurrence of the Milestone Event occurs prior to the Initial Exercise Date, the 90th day following the Initial Exercise Date, subject to the satisfaction of the Equity Conditions (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Termination Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), but not thereafter, to subscribe for and purchase from Lineage Cell Therapeutics, Inc., a California corporation (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), up to 7,894,737 Common Shares (as subject to adjustment hereunder, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrant Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  The purchase price of one Common Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For purposes of this Warrant, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Conditions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, with respect to a given date of determination: (i) on such applicable date of determination one or more registration statements (each, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Acceleration Registration Statement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) shall be effective and the prospectus contained therein shall be available on such applicable date of determination (with, for the avoidance of doubt, any Warrant Shares previously issued pursuant to such prospectus deemed unavailable) for the issuance of all the Warrant Shares issuable upon exercise of this Warrant in connection with the event requiring such determination (such applicable aggregate number of Common Shares, each, a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Required Minimum Securities Amount</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;); (ii) on each day during the period of (x) the ninety (90) calendar following the public disclosure of the occurrence of the Milestone Event, subject to the conditions herein or (y) if the date of the public disclosure of the occurrence of the Milestone Event occurs prior to the Initial Exercise Date, the 90th day following the Initial Exercise Date, subject to the conditions herein (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity Conditions Measuring Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), the Common Shares are listed or designated for quotation (as applicable) on a Trading Market and shall not have been suspended from trading on a Trading Market (other than suspensions of not more than two (2) days and occurring prior to the applicable date of determination due to business announcements by the Company) nor shall delisting or suspension by a Trading Market have been threatened (with a reasonable prospect of delisting occurring after giving effect to all applicable notice, appeal, compliance and hearing periods) or reasonably likely to occur or pending as evidenced by (A) a writing by such Trading Market or (B) the Company falling below the minimum listing maintenance requirements of such Trading Market on which the Common Shares are then listed or designated for quotation (as applicable); (iii) during the Equity Conditions Measuring Period, the Company shall have delivered all Warrant Shares issuable upon exercise of this Warrant on a timely basis in accordance herewith and all other share capital required to be delivered by the Company on a timely basis as set forth in the other Transaction Documents; (iv) any Warrant Shares to be issued in connection with the event</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">requiring determination may be issued in full without violating the rules or regulations of the Trading Market on which the Common Shares are then listed or designated for quotation (as applicable); (v) on each day during the Equity Conditions Measuring Period, no public announcement of a pending, proposed or intended Fundamental Transaction shall have occurred which has not been abandoned, terminated or consummated; (vi) the Company shall have no knowledge of any fact that would reasonably be expected to cause the applicable Acceleration Registration Statement to not be effective or the prospectus contained therein to not be available for the issuance of all the Warrant Shares issuable upon exercise of this Warrant in connection with the event requiring such determination and no Public Information Failure (as defined below) exists or is continuing; (vii) the Holder shall not be in possession of any material, non-public information provided to any of them by the Company, any of its Subsidiaries or any of their respective affiliates, employees, officers, representatives, agents or the like; (viii) on each day during the Equity Conditions Measuring Period, the Company otherwise shall have been in compliance with each, and shall not have breached any representation or warranty in any material respect (other than representations or warranties subject to material adverse effect or materiality, which may not be breached in any respect) or any covenant or other term or condition of any Transaction Document, including, without limitation, the Company shall not have failed to timely make any payment pursuant to any Transaction Document; (ix) on the applicable date of determination all Warrant Shares to be issued in connection with the event requiring this determination may be issued in full without resulting in a breach of any provision of the Common Warrants; (x) the Warrant Shares to be issued in connection with the event requiring this determination are duly authorized and listed and eligible for trading without restriction on a Trading Market.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Public Information Failure</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means at any time either (x) the Company fails for any reason to satisfy the requirements of Rule 144(c)(1), including, without limitation, the failure to satisfy the current public information requirement under Rule 144(c) or (y) the Company has ever been an issuer described in Rule 144(i)(1)(i) or becomes such an issuer in the future, and the Company shall fail to satisfy any condition set forth in Rule 144(i)(2).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 1</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Definitions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Purchase Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), dated November 19, 2024, among the Company and the purchasers signatory thereto.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exercise</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.14287551026968%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exercise of Warrant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notice of Exercise</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;).  Within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&#x2019;s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in </font></div></div>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the applicable Notice of Exercise.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required.  Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation as soon as reasonably practicable following the date on which the final Notice of Exercise is delivered to the Company, and in any event within three (3) Trading Days of such date. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased.  The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Trading Day of receipt of such notice.  </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.14287551026968%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exercise Price</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The exercise price per Common Share under this Warrant shall be </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$0.91</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, subject to adjustment hereunder (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exercise Price</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.14287551026968%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cashless Exercise</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised, in whole or in part, at such time by means of a &#x201c;cashless exercise&#x201d; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B)*(X)] by (A), where:</font></div></div>
  <p style="margin-left:13.333%;text-indent:-7.209%;padding-left:5.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(A) = as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &#x201c;regular trading hours&#x201d; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) the Bid Price of the Common Share on the principal Trading Market as reported by Bloomberg L.P. (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Bloomberg</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) as of the time of the Holder&#x2019;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &#x201c;regular trading hours&#x201d; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &#x201c;regular trading hours&#x201d; on a Trading Day) pursuant to Section 2(a) hereof, or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &#x201c;regular trading hours&#x201d; on such Trading Day;</font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:13.333%;text-indent:-8.333%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:13.333%;text-indent:-8.333%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(B) = the Exercise Price of this Warrant, as adjusted hereunder; and</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="margin-left:13.333%;text-indent:-8.333%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:13.333%;text-indent:-7.209%;padding-left:5.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(X) = the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</font></p>
  <p style="margin-left:13.333%;text-indent:-7.209%;padding-left:5.84%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;Bid Price</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Share is then listed or quoted on a Trading Market, the bid price of the Common Share for the time in question (or the nearest preceding date) on the Trading Market on which the Common Share is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)  if the OTCQB Venture Market (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OTCQB</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) or the OTCQX Best Market (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OTCQX</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) is not a Trading Market, the volume weighted average price of the Common Share for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Share is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Share are then reported on The Pink Open Market operated by the OTC Markets, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pink Market</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per Common Share so reported, or (d) in all other cases, the fair market value of a share of Common Share as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">VWAP</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Share is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Share for such date (or the nearest preceding date) on the Trading Market on which the Common Share is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)  if the OTCQB or the OTCQX is not a Trading Market, the volume weighted average price of the Common Share for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Share is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Share are then reported on the Pink Market, the most recent bid price per Common Share so reported, or (d) in all other cases, the fair market value of a Common Share as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised.  The Company agrees not to take any position contrary to the foregoing.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.14287551026968%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Mechanics of Exercise</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </font></div></div>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:20%;text-indent:8.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.33375%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">i.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Delivery of Warrant Shares Upon Exercise</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder&#x2019;s or its designee&#x2019;s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DWAC</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a certificate, registered in the Company&#x2019;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earlier of (i) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company (if applicable), and (ii) the number of Trading Days comprising the Standard Settlement Period, in each case (i) or (ii), after the delivery to the Company of the Notice of Exercise and subject to the payment of aggregate Exercise Price to the Company (if applicable) (such date, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrant Share Delivery Date</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by the Warrant Share Delivery Date.  If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Share on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third (3</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">rd</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Standard Settlement Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the standard settlement period, expressed in a number of Trading Days, on the Company&#x2019;s primary Trading Market with respect to the Common Share as in effect on the date of delivery of the Notice of Exercise. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:20%;text-indent:8.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.33375%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">ii.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Delivery of New Warrants Upon Exercise</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.</font></div></div>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:20%;text-indent:8.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.33375%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">iii.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rescission Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date (subject to receipt of the aggregate exercise price for the applicable exercise (other than in the case of a cashless exercise)), then the Holder will have the right to rescind such exercise.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:20%;text-indent:8.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.33375%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">iv.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date (subject to receipt of the aggregate exercise price for the applicable exercise (other than in the case of a cashless exercise)), and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&#x2019;s brokerage firm otherwise purchases, Common Shares to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Buy-In</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&#x2019;s total purchase price (including brokerage commissions, if any) for the Common Shares so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of Common Shares that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder.  For example, if the Holder purchases Common Shares having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of Common Shares with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss.  Nothing herein shall limit a Holder&#x2019;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#x2019;s failure to timely deliver Common Shares upon exercise of the Warrant as required pursuant to the terms hereof.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:20%;text-indent:8.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.33375%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">v.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Fractional Shares or Scrip</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant.  As to any fraction of a share which the Holder would otherwise </font></div></div>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:20%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:20%;text-indent:8.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.33375%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">vi.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Charges, Taxes and Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">provided</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">however</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.  The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:20%;text-indent:8.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.33375%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">vii.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Closing of Books</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Company will not close its shareholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.14287551026968%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reserved</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  </font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain Adjustments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.14287551026968%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Dividends and Splits</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on its Common Shares or any other equity or equity equivalent securities payable in Common Shares (which, for avoidance of doubt, shall not include any Common Shares issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding Common Shares into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding Common Shares into a smaller number of shares, or (iv) issues by reclassification of Common Shares any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of Common Shares (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of Common Shares outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged.  Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of shareholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re&#x2011;classification.</font></div></div>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.14287551026968%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subsequent Rights Offerings</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Share Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of Common Shares (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Purchase Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of Common Shares acquirable upon complete exercise of this Warrant immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of Common Shares are to be determined for the grant, issue or sale of such Purchase Rights. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.14287551026968%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pro Rata Distributions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of Common Shares, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Distribution</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of Common Shares acquirable upon complete exercise of this Warrant immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of Common Shares are to be determined for the participation in such Distribution.  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.14287551026968%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fundamental Transaction</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company (or any Subsidiary), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of the assets of the Company in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Shares are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of greater than 50% of the outstanding Common Shares or greater than 50% of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Shares or any compulsory share exchange pursuant to which the Common Shares is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires greater than 50% of the outstanding Common Shares or greater than 50% of the voting power of the common equity of the Company, except, in each case of the preceding clauses (i) through and including (v), actions taken solely in connection with an internal reorganization (each a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fundamental Transaction</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable </font></div></div>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;" id="x__cp_change_0"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder, the number of Common Shares of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Alternate Consideration</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) receivable as a result of such Fundamental Transaction by a holder of the number of Common Shares for which this Warrant is exercisable immediately prior to such Fundamental Transaction.  For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one Common Share in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration.  If holders of Common Shares are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&#x2019;s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction; provided, however, that, if the Fundamental Transaction is not within the Company's control, including not approved by the Company's Board of Directors, the Holder shall only be entitled to receive from the Company or any Successor Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Shares of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Shares are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; provided, further, that if holders of Common Shares of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of Common Shares will be deemed to have received common stock of the Successor Entity (which Successor Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction.  &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Black Scholes Value</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d; means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the &#x201c;OV&#x201d; function on Bloomberg determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> lesser of 100% and the </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">100 day volatility obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the public announcement of the applicable contemplated Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the highest VWAP during the period beginning on the Trading Day immediately preceding the public</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announcement of the applicable Fundamental Transaction (or, if earlier, the consummation of the Fundamental Transaction) and ending on the Trading Day of the Holder&#x2019;s request pursuant to this Section 3(d), (D) a remaining option time equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds (or such other consideration) within the later of (i) five Business Days of the Holder&#x2019;s election and (ii) the date of consummation of the Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Successor Entity</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the Common Shares acquirable and receivable upon exercise of this Warrant prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the Common Shares pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the term &#x201c;Company&#x201d; under this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction, each and every provision of this Warrant and the other Transaction Documents referring to the &#x201c;Company&#x201d; shall refer instead to each of the Company and the Successor Entity or Successor Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly and severally with the Company, may exercise every right and power of the Company prior thereto and the Successor Entity or Successor Entities shall assume all of the obligations of the Company prior thereto under this Warrant and the other Transaction Documents with the same effect as if the Company and such Successor Entity or Successor Entities, jointly and severally, had been named as the Company herein. For the avoidance of doubt, the Holder shall be entitled to the benefits of the provisions of this Section 3(d) regardless of (i) whether the Company has sufficient authorized Common Shares for the issuance of Warrant Shares and/or (ii) whether a Fundamental Transaction occurs prior to the Initial Exercise Date.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.14287551026968%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Calculations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of Common Shares deemed to be issued and outstanding as of a given date shall be the sum of the number of Common Shares (excluding treasury shares, if any) issued and outstanding.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.14287551026968%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notice to Holder</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  </font></div></div>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:20%;text-indent:8.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.33375%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">i.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adjustment to Exercise Price</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by a permitted notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:20%;text-indent:8.333%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:6.33375%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">ii.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notice to Allow Exercise by Holder</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Shares, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Shares, (C) the Company shall authorize the granting to all holders of the Common Shares rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of the shareholders of the Company shall be required in connection with any reclassification of the Common Shares, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Share is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Shares of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Shares of record shall be entitled to exchange their shares of the Common Shares for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. Upon occurrence of the Milestone Event, the Company shall notify the Holder as soon as practicable thereafter.  To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.  The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</font></div></div>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transfer of Warrant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.14287551026968%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Transferability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer.  Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled.  Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full.  The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.14287551026968%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">New Warrants</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney.  Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Issue Date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto. </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.14287551026968%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrant Register</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrant Register</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#x201d;), in the name of the record Holder hereof from time to time.  The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Section 5</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Miscellaneous</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.14287551026968%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No Rights as Shareholder Until Exercise; No Settlement in Cash</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a shareholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3.  Without limiting any rights of a Holder to receive Warrant Shares on a &#x201c;cashless exercise&#x201d; pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this Warrant.  </font></div></div>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.14287551026968%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Loss, Theft, Destruction or Mutilation of Warrant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.14287551026968%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Saturdays, Sundays, Holidays, etc</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Trading Day, then, such action may be taken or such right may be exercised on the next succeeding Trading Day.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.14287551026968%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Authorized Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  </font></div></div>
  <p style="margin-left:13.333%;text-indent:15.385%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Shares a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.  The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant.  The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Shares may be listed.  The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </font></p>
  <p style="margin-left:13.333%;text-indent:7.692%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment.  Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="margin-left:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</font></p>
  <p style="margin-left:13.333%;text-indent:7.692%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.14287551026968%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Jurisdiction</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with the provisions of the Purchase Agreement.  </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.14287551026968%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restrictions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.14287551026968%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nonwaiver and Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder&#x2019;s rights, powers or remedies, notwithstanding the fact that the right to exercise this Warrant terminates on the Termination Date.  Without limiting any other provision of this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&#x2019; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.14287551026968%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">h)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notices</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance with the notice provisions of the Purchase Agreement.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.14287551026968%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Limitation of Liability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common Shares or as a shareholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.14287551026968%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">j)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Remedies</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant.  The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions </font></div></div>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.14287551026968%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">k)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Successors and Assigns</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.  The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.14287551026968%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">l)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amendment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and the Holder of this Warrant, on the other hand.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.14287551026968%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">m)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Severability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;text-indent:7.143%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:5.14287551026968%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">n)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Headings</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.  The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">********************</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">(Signature Page Follows)</font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <table style="border-spacing:0;table-layout:auto;width:63.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Lineage Cell Therapeutics, Inc.</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-style:italic;font-kerning:none;min-width:fit-content;">/s/Brian M. Culley</font><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Name: Brian M. Culley</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Title:   Chief Executive Officer</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTICE OF EXERCISE</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To:	</font><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lineage Cell Therapeutics, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:2.537%;text-indent:13.68%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.3219067748786717%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(1)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:2.537%;text-indent:13.68%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.3219067748786717%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(2)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Payment shall take the form of (check applicable box):</font></div></div>
  <p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[  ] in lawful money of the United States; or</font></p>
  <p style="margin-left:20%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[  ] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</font></p>
  <div class="item-list-element-wrapper" style="margin-left:2.537%;text-indent:13.68%;font-size:0;margin-top:0;justify-content:flex-start;margin-bottom:12pt;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:2.3219067748786717%;word-break:keep-all;text-indent:0;display:inline-flex;justify-content:flex-start;">(3)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">			_______________________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">			</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Warrant Shares shall be delivered to the following DWAC Account Number:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">			_______________________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">			</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">			_______________________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">			</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">			_______________________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">[SIGNATURE OF HOLDER]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Name of Investing Entity: ________________________________________________________________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Signature of Authorized Signatory of Investing Entity</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">: _________________________________________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Name of Authorized Signatory: ___________________________________________________________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Title of Authorized Signatory: ____________________________________________________________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Date: ________________________________________________________________________________________</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">EXHIBIT B</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASSIGNMENT FORM</font></p>
  <p style="text-indent:1.947%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> (To assign the foregoing Warrant, execute this form and supply required information.  Do not use this form to exercise the Warrant to purchase shares.)</font></p>
  <p style="text-indent:1.947%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</font></p>
  <table style="border-spacing:0;table-layout:auto;width:91.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:50%;box-sizing:content-box;"></td>
    <td style="width:50%;box-sizing:content-box;"></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Name:</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Please Print)</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Address:</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Phone Number:</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Email Address:</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Please Print)</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">______________________________________</font></p><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">______________________________________</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dated: _______________ __, ______</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Holder&#x2019;s Signature:</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:30pt;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Holder&#x2019;s Address:</font></p></td>
    <td style="padding-top:0in;padding-left:0.075in;vertical-align:top;padding-bottom:0in;padding-right:0.075in;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:30pt;text-align:justify;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.4in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>lctx-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img176613450_0.jpg" alt="img176613450_0.jpg" style="width:307px;height:63px;"></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lineage Cell Therapeutics Announces CLOSING OF SECOND TRANCHE OF PREVIOUSLY ANNOUNCED Registered Direct Offering</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lineage Has Now Received $30 Million in Gross Proceeds and May Receive an Additional $36 Million in Gross Proceeds Upon the Full Exercise of OpRegen</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Clinical Milestone-linked Warrants</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CARLSBAD, CA &#x2013; January 27, 2025 </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">- </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lineage Cell Therapeutics, Inc.</font></font><font style="color:#0563c1;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the closing of the second tranche of its previously </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">announced</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> registered direct offering of an aggregate of up to $66 million. The Company had previously received $24 million in gross proceeds at the closing of the first tranche in November 2024.  Today, the Company received an additional $6 million in gross proceeds at the closing of the second tranche.  In addition, the Company may receive up to an additional $36 million of gross proceeds upon the exercise in full on a cash basis of the clinical milestone-linked warrants issued in the offering.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lineage obtained shareholder approval of the issuance of the securities at the closing of the second tranche, in satisfaction of applicable NYSE American rules. Lineage shareholders approved the issuance of 7,894,737 common shares and accompanying warrant to purchase an aggregate of up to 7,894,737 common shares, at a combined purchase price of $0.76 per common share and accompanying warrant, to Broadwood Partners, L.P., an affiliate of Neal Bradsher, a member of Lineage&#x2019;s board of directors. Such warrant is exercisable for one common share at an exercise price of $0.91 per common share commencing on May 21, 2025 and will expire on the earlier of (a) May 21, 2028 and (b) the 90th day following the date of the public disclosure of the intent to advance OpRegen (also known as RG6501) into a multi-center phase 2 or 3 clinical trial which includes a control or comparator arm, or if the date of such public disclosure occurs prior to May 21, 2025, then the 90</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> day following May 21, 2025.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The securities described above were offered and sold by Lineage in a registered direct offering pursuant to a &#x201c;shelf&#x201d; registration statement on Form S-3 (File No. 333-277758) filed with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on March 7, 2024, and which was declared effective by the SEC on May 14, 2024. The offering of the securities in the registered direct offering was made only by means of a base prospectus and a prospectus supplement that forms a part of the effective registration statement. A final prospectus supplement and the accompanying base prospectus relating to the offering were filed with the SEC and are available on the SEC&#x2019;s website at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying base prospectus may also be obtained from H.C. Wainwright &amp; Co., LLC, who served as the exclusive placement agent for the offering, at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">About Lineage Cell Therapeutics, Inc.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, &#x201c;off-the-shelf,&#x201d; cell therapies to address unmet medical needs. Lineage&#x2019;s programs are based on its proprietary cell-based technology platform and associated development and manufacturing capabilities. From this platform, Lineage designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions similar or identical to cells found naturally in the human body. These cells are created by applying directed differentiation protocols to established, well-characterized, and self-renewing pluripotent cell lines. These protocols generate cells</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with characteristics associated with specific and desired developmental lineages. Cells derived from such lineages are transplanted into patients in an effort to replace or support cells that are absent or dysfunctional due to degenerative disease, aging, or traumatic injury, and to restore or augment the patient&#x2019;s functional activity. Lineage&#x2019;s neuroscience focused pipeline currently includes: (i) OpRegen, a retinal pigment epithelial cell therapy in Phase 2a development under a worldwide collaboration with Roche and Genentech, a member of the Roche Group, for the treatment of geographic atrophy secondary to age-related macular degeneration; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of spinal cord injuries; (iii) ReSonance&#153; (ANP1), an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; (iv) PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and (v) RND1, a novel hypoimmune induced pluripotent stem cell line being developed in collaboration with Factor Bioscience Limited. For more information, please visit </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">www.lineagecell.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or follow the company on X/Twitter </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">@LineageCell</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Forward-Looking Statements</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lineage cautions you that all statements, other than statements of historical fact, in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as &#x201c;believe,&#x201d; &#x201c;aim,&#x201d; &#x201c;may,&#x201d; &#x201c;will,&#x201d; &#x201c;estimate,&#x201d; &#x201c;continue,&#x201d; &#x201c;anticipate,&#x201d; &#x201c;design,&#x201d; &#x201c;intend,&#x201d; &#x201c;expect,&#x201d; &#x201c;could,&#x201d; &#x201c;can,&#x201d; &#x201c;plan,&#x201d; &#x201c;potential,&#x201d; &#x201c;predict,&#x201d; &#x201c;seek,&#x201d; &#x201c;should,&#x201d; &#x201c;would,&#x201d; &#x201c;contemplate,&#x201d; &#x201c;project,&#x201d; &#x201c;target,&#x201d; &#x201c;tend to,&#x201d; or the negative version of these words and similar expressions. Lineage&#x2019;s forward-looking statements are based upon its current expectations and beliefs and involve assumptions that may never materialize or may prove to be incorrect. Such statements include, but are not limited to, statements relating to the total potential amount of proceeds from the offering, the exercise of the warrants in cash prior to their expiration, and the exercise of the warrants upon the achievements of the clinical milestone event or otherwise prior to their expiration. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the risks that the warrants may not be exercised or, if exercised, the exercise price may not be paid in cash, and those risks and uncertainties inherent in Lineage&#x2019;s business and other risks discussed in Lineage&#x2019;s filings with the SEC. Further information regarding these and other risks is included under the heading &#x201c;Risk Factors&#x201d; in Lineage&#x2019;s periodic reports with the SEC, including Lineage&#x2019;s most recent Annual Report on Form 10-K filed with the SEC and its other subsequent reports, which are available from the SEC&#x2019;s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. All forward-looking statements are expressly qualified in their entirety by these cautionary statements.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lineage Cell Therapeutics, Inc. IR</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ioana C. Hone</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(ir@lineagecell.com)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(442) 287-8963</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Russo Partners &#x2013; Media Relations</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nic Johnson or David Schull</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Nic.johnson@russopartnersllc.com)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(David.schull@russopartnersllc.com)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(212) 845-4242</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">###</font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>img176613450_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img176613450_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %H!LP# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHH)P*  G K'N?%.B6DACEU"/<.NP%\?\ ?(-<-XI\43:I<R6E
MK*4L4./E./-/J?;T%<Q7LX?*N:/-5=O)'C8C->67+25_-GK7_"9^'_\ G_\
M_(,G_P 31_PF?A__ )__ /R#)_\ $UY+171_9-'N_P /\CG_ +6K]E^/^9ZU
M_P )GX?_ .?_ /\ (,G_ ,31_P )GX?_ .?_ /\ (,G_ ,37DM%']DT>[_#_
M "#^UJ_9?C_F>M?\)GX?_P"?_P#\@R?_ !-'_"9^'_\ G_\ _(,G_P 37DM%
M']DT>[_#_(/[6K]E^/\ F>M?\)GX?_Y__P#R#)_\31_PF?A__G__ /(,G_Q-
M>2T4?V31[O\ #_(/[6K]E^/^9ZU_PF?A_P#Y_P#_ ,@R?_$T?\)GX?\ ^?\
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MV-:->9_"/_F,?]L/_:E>F4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5'<3Q6MM+<3/LBB0N['LH&2?RJ2LSQ'_R*^K_]>4W_ * : */_  G7
MAK_H*Q_]\/\ X4L?C;PY+(L::I&7<A5&Q^2?PKP:K.F_\A2T_P"NR?\ H0H
M^D**** "BBB@ HHHH **** "D9@BEF. !DFEJ*Y_X]9O]P_RH P_^$Z\-?\
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M\?\ "=>&O^@K'_WP_P#A1_PG7AK_ *"L?_?#_P"%>#T4 >\?\)UX:_Z"L?\
MWP_^%'_"=>&O^@K'_P!\/_A7@]% 'O'_  G7AK_H*Q_]\/\ X4?\)UX:_P"@
MK'_WP_\ A7@]% 'O'_"=>&O^@K'_ -\/_A1_PG7AK_H*Q_\ ?#_X5X/10![Q
M_P )UX:_Z"L?_?#_ .%'_"=>&O\ H*Q_]\/_ (5X/10!]#Z7K^EZTTJZ==K.
M8@"X52,9Z=1[5I5Y=\)/^/K5?]R/^;5ZC0 4444 %%%% !1110 4444 %%%%
M !1110 5'//%;6\D\SA(HE+NQZ* ,DU)7%_$O5?L/AL6:-B6]?9_P <M_0?C
M0!I_\)UX:_Z"L?\ WP_^%'_"=>&O^@K'_P!\/_A7@]% 'TE:7<%_:1W5K*)8
M)!N1QT(J>O/_ (6:K]HTFYTQV^>V??&/]ANN/H<_]]5Z!0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !15>]O[73;5KF\G2"%>KN<?A[GVKS77
M_BC-(S0:)%Y2=/M$JY8_[J]!^.?H* /3;BZM[2$S7,\<,8ZO(X4#\37,WWQ%
M\.V1(6YDN6'401D_J<#]:\:O=0O-1G,U[<RSR?WI&)Q]/2JU 'J<_P 6K52?
ML^DS2#_II,$_D#50_%N?/&CQ_P#?\_\ Q->;T4 >E)\6Y ?WFC*1_LW&/_9:
MT;7XK:7(0+FQNH?=-K@?J*\DHH ]\T_QCH&IE5@U*)9#T27,9SZ?-C/X5N@Y
M&17S-6QH_BC6-#8?8[QQ$/\ EC)\R'\#T_#% 'T#17%>'?B-IVJE+?4 ME='
MC+']VQ]CV^A_.NUH **** "BBB@ HHHH **** "BBB@ HHHH PKCQGX>M;F6
MWFU.-)8G*.I1N&!P1T]:C_X3KPU_T%8_^^'_ ,*\:\1_\C1J_P#U^S?^AFLR
M@#WC_A.O#7_05C_[X?\ PH_X3KPU_P!!6/\ [X?_  KP>B@#WC_A.O#7_05C
M_P"^'_PH_P"$Z\-?]!6/_OA_\*\'HH ]X_X3KPU_T%8_^^'_ ,*/^$Z\-?\
M05C_ .^'_P *\'HH ]X_X3KPU_T%8_\ OA_\*/\ A.O#7_05C_[X?_"O!Z*
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M !%>P44 >/\ _"JM=_Y^]._[^/\ _$4?\*JUW_G[T[_OX_\ \17L%% 'C_\
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MO_0S690!UND_#S5M8TN#4+>XLEBF!*B1W##!(YPI]*N?\*JUW_G[T[_OX_\
M\17?^!?^1+TS_<;_ -#:NAH \?\ ^%5:[_S]Z=_W\?\ ^(H_X55KO_/WIW_?
MQ_\ XBO8** /'_\ A56N_P#/WIW_ '\?_P"(H_X55KO_ #]Z=_W\?_XBO8**
M /'_ /A56N_\_>G?]_'_ /B*/^%5:[_S]Z=_W\?_ .(KV"B@#Q__ (55KO\
MS]Z=_P!_'_\ B*/^%5:[_P _>G?]_'_^(KV"B@#Q_P#X55KO_/WIW_?Q_P#X
MBO4=$LI--T.RLIF1I8(5C8H202!VS5^B@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH \^\5>#YA<27^F1F2-R6D@4<J>Y4=Q
M[5Q+*58JP((X(/:O=ZK7&GV5VVZYL[>8^LD8;^8KU</FDJ<>6HKGDXC*XU)<
MU-V/$**]I_L/2?\ H%V7_@.G^%']AZ3_ - NR_\  =/\*Z/[7A_*SG_LB?\
M,CQ:BO:?[#TG_H%V7_@.G^%']AZ3_P! NR_\!T_PH_M>'\K#^R)_S(\6HKVG
M^P])_P"@79?^ Z?X4?V'I/\ T"[+_P !T_PH_M>'\K#^R)_S(\6HKVG^P])_
MZ!=E_P" Z?X4?V'I/_0+LO\ P'3_  H_M>'\K#^R)_S(\6HKVG^P])_Z!=E_
MX#I_A1_8>D_] NR_\!T_PH_M>'\K#^R)_P R/%JU]%\.7VM3+Y49CM\_-.X^
M4?3U/M7J:Z-I:,&33;-6'0B!0?Y5=      '0"LZN;-JU.-GYFE+*$I7J2NO
M(K:?80:98Q6ENN(XQCW)[D^YJU117CMN3NSV8I15D%%%%(84444 %%%% !11
M10 4444 >2?%?_D/67_7K_[,U<#7??%?_D/67_7K_P"S-7 T >F_"/\ YC'_
M &P_]J5Z97F?PC_YC'_;#_VI7IE !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MIO\ R%+3_KLG_H0JM5G3?^0I:?\ 79/_ $(4 ?2%%%% !1110 4444 %%%%
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M HHHH *\S^+G_,'_ .V__M.O3*\S^+G_ #!_^V__ +3H \RKT/X3?\A34?\
MKBO_ *%7GE>A_";_ )"FH_\ 7%?_ $*@#U:BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *QO%6J_V-X;O;L-B0)LB_WVX'Y9
MS^%;->7_ !6U7=-9Z2C<(//E'N>%_P#9OSH \VK1T'3&UC7;.P .)9 '([*.
M6/Y UG5Z-\*=*\R[O-5=?EC7R(S_ +1Y;\AC_OJ@#U)5"*%4 *!@ =J6BB@#
MP+Q=I7]C^)[RV5=L3/YD7^ZW(_+D?A6'7J7Q6TKS+6SU5%YC)@E/^R>5_(Y_
M.O+: /=? NJ_VMX4M69LRVX\B3ZKT_\ '<&NDKR3X6ZK]FUFXTUVPETFY!_M
MKS^HS^0KUN@ HHHH **** "BBB@ HHHH **** $9E1"S$!0,DGL*^>O$.JMK
M6NW=^2=LC_NP>R#A1^0%>Q>.]1.F^$;QE;$DX$"?\"Z_^.[J\*H *]D^&^@C
M3=#_ +0F3%S>X89ZK'_"/QZ_B*\LT+3&UC7+.P&<32 ,1V4<L?R!KZ&1%CC6
M-%"HH 50. !VH =1110 4444 %%%% !1110 4444 %!&1@T44 >">,=$&A>(
M[BVC7%O)^]A]E/;\#D?A6#7L7Q'\/7.L6-G<6-NTUS Y0HG4HPZ_@0/SKSK_
M (0WQ%_T"+G\A0!V?PHU0M%?:4[?<(GC'L>&_P#9?SKTFO(_!.@Z]I'BFUN+
MC39X[=@T<K$< $''ZXKUR@ HHHH **** "BBB@ HHHH ^>?$?_(T:O\ ]?LW
M_H9K,K3\1_\ (T:O_P!?LW_H9K,H ]X\"_\ (EZ9_N-_Z&U=#7/>!?\ D2],
M_P!QO_0VKH: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBN6\1^,8=)
MD:TM$6>['WB3\D?U]3[5I2HSJRY8*[,JM:%*/--V1U-%>13^+=<GD+F_=/18
MP% _2H_^$HUO_H)3_F*]%935_F1Y[S>E_*SV&BO'O^$HUO\ Z"4_YBC_ (2C
M6_\ H)3_ )BC^R:O\R%_:]+^5GL-%>/?\)1K?_02G_,4?\)1K?\ T$I_S%']
MDU?YD']KTOY6>PT5X]_PE&M_]!*?\Q1_PE&M_P#02G_,4?V35_F0?VO2_E9[
M#17CW_"4:W_T$I_S%'_"4:W_ -!*?\Q1_9-7^9!_:]+^5GL-%>/?\)1K?_02
MG_,4Y/%6N1N&&HRDCLP!'Y$4?V35_F0_[7I?RO\  ]?HKBM!\=+<RI:ZHB1.
MW"SKPI/N.WUZ?2NUK@K4*E&7+-'?1KTZT>:#"BBBL38**Y[Q%XKM]#_<(HGO
M",^7G 4>K'^E<+<^,-<N9"WVPQ#LD2A0/ZUW4,!6K1YEHO,X:^84:,N5ZOR/
M6Z*\>_X2C6_^@E/^8H_X2C6_^@E/^8K?^R:O\R.?^UZ7\K/8:*\>_P"$HUO_
M *"4_P"8H_X2C6_^@E/^8H_LFK_,@_M>E_*SV&BO'O\ A*-;_P"@E/\ F*/^
M$HUO_H)3_F*/[)J_S(/[7I?RL]AHKQ[_ (2C6_\ H)3_ )BC_A*-;_Z"4_YB
MC^R:O\R#^UZ7\K/8:*\>_P"$HUO_ *"4_P"8H_X2C6_^@E/^8H_LFK_,@_M>
ME_*SV&BO'U\4ZXK C49LCUP?Z5T>B>/7:58-65=K' G08Q_O#^H_*LZF65H1
MNK/T-:6:49RL[KU.]HI%974,K!E89!!R"*6O./1"BBB@ HHHH **** "BBB@
M HHHH \D^*__ "'K+_KU_P#9FK@:[[XK_P#(>LO^O7_V9JX&@#TWX1_\QC_M
MA_[4KTRO,_A'_P QC_MA_P"U*],H **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ K,\1_P#(KZO_ ->4W_H!K3K,\1_\BOJ__7E-_P"@&@#YYJSI
MO_(4M/\ KLG_ *$*K59TW_D*6G_79/\ T(4 ?2%%%% !1110 4444 %%%% !
M45S_ ,>LW^X?Y5+45S_QZS?[A_E0!\UT444 ?2EM_P >L/\ N#^52U%;?\>L
M/^X/Y5+0!5U'3[?5=/FLKI-T,R[6'<>A'N.M>!:[HUQH.K36%P,E#E'QPZGH
MPKZ'KF/&OAA?$6DEH5'VZW!:$_WO5#]?Y_C0!X;7JOPW\4_:8!H=Y)^^B&;9
MF/WE'\/U';V^E>5LK(Q5E*L#@@C!!I]O<2VMQ'<02&.6-@Z.O4$=#0!]*T5A
M^%?$,7B/1TN5PMPGR3QC^%O7Z'J/_K5N4 %%%% !1110 5Y)\5_^0]9?]>O_
M +,U>MUY)\5_^0]9?]>O_LS4 <#7J/PD_P"/75?]^/\ DU>75ZC\)/\ CUU7
M_?C_ )-0!Z11110 4444 %%%% !1110 5YG\7/\ F#_]M_\ VG7IE>9_%S_F
M#_\ ;?\ ]IT >95Z'\)O^0IJ/_7%?_0J\\KT/X3?\A34?^N*_P#H5 'JU%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 C,$4L
MQ 4#))[5\\^(-3.L:]>7Y)*RR'9GL@X4?D!7L/CW5?[*\*7.QL37/[A.>?FZ
MG_OG->&4 %>^^$-*_L?PQ9VS+ME9/-E'?<W)'X<#\*\<\)Z5_;'B:RM67=$'
M\R7_ '%Y/Y]/QKW^@ HHHH S=?TP:QH5Y8$#=+&0F>SCE3^8%?/+*R,58$,#
M@@]C7TQ7AGCW2_[+\67.U<17/^D)_P "Z_\ CP- &'IE])IFIVU]%]^"17 ]
M<'D?CTKZ+MYX[JVBN(6W12H'1O4$9%?-5>S_  UU7[?X9%J[9ELG\L^NP\J?
MYC\* .RHHHH **** "BBB@ HHHH **** /-/BS>X33;$'J7F8?D!_-J\QKL_
MB=<&;Q;Y?:&W1/SRW_LU<90!W_PJL!-K-Y?,,BWA"+_O,?\ !3^=>M5PWPLM
M1%X;GN"/FFN3S[  #]<UW- !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% 'SSXC_P"1HU?_ *_9O_0S696GXC_Y&C5_
M^OV;_P!#-9E 'O'@7_D2],_W&_\ 0VKH:Y[P+_R)>F?[C?\ H;5T- !1110
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M_P QC_MA_P"U*],H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%0:!1110 4444 %%%% !1110!Y)\5_\ D/67_7K_ .S-7 UWWQ7_ .0]9?\
M7K_[,U<#0!Z;\(_^8Q_VP_\ :E>F5YG\(_\ F,?]L/\ VI7IE !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %9GB/\ Y%?5_P#KRF_] -:=9GB/
M_D5]7_Z\IO\ T T ?/-6=-_Y"EI_UV3_ -"%5JLZ;_R%+3_KLG_H0H ^D***
M* "BBB@ HHHH **** "HKG_CUF_W#_*I:BN?^/6;_</\J /FNBBB@#Z4MO\
MCUA_W!_*I:BMO^/6'_<'\JEH **** "L;Q/X?A\1:/):/A9E^>"0_P #_P"!
MZ&MFB@#YKNK::RNI;:XC,<T3%'4]B*C!*D$$@CD$5ZO\2/"WVRV.M6:?Z1"N
M+A0/OH/XOJ/Y?2O)Z /;O WB@>(-+\FX<?;[8 2YZNO9_P#'W^M=77SKHVK7
M.AZI#?VI^>,\J3PZ]U/L:]^TK4[?6--AOK5MT4JY /53W!]P: +E%%% !7DG
MQ7_Y#UE_UZ_^S-7K=>2?%?\ Y#UE_P!>O_LS4 <#7J/PD_X]=5_WX_Y-7EU>
MH_"3_CUU7_?C_DU 'I%%%% !1110 4444 %%%% !7F?Q<_Y@_P#VW_\ :=>F
M5YG\7/\ F#_]M_\ VG0!YE4UO9W-XS+;6\T[*,D1(6Q^50UZ'\)O^0IJ/_7%
M?_0J .*_L35?^@9>_P#@.W^%']B:K_T#+W_P';_"OHNB@#YT_L35?^@9>_\
M@.W^%']B:K_T#+W_ ,!V_P *^BZ* /G3^Q-5_P"@9>_^ [?X4?V)JO\ T#+W
M_P !V_PKZ+HH ^=/[$U7_H&7O_@.W^%']B:K_P! R]_\!V_PKZ+HH ^=/[$U
M7_H&7O\ X#M_A6MX8TC4H?%&F22Z?=HBW*%F:%@ ,]2<5[K10 4444 %%%%
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MNK?FBG^M<]0![YX-_P"1/TO_ *XC^9K=KF? $HE\%:?ZJ'4_@[5TU !1110
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M'_;#_P!J5Z97F?PC_P"8Q_VP_P#:E>F4 %%%% !1110 4444 %%%% !1110
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M_P"^$_\ BJU^I8C^1F7UW#_SHZVBN2_X6'I/_/O>_P#?"?\ Q5'_  L/2?\
MGWO?^^$_^*H^I8C^1A]=P_\ .CK:*Y+_ (6'I/\ S[WO_?"?_%4?\+#TG_GW
MO?\ OA/_ (JCZEB/Y&'UW#_SHZVBN2_X6'I/_/O>_P#?"?\ Q5'_  L/2?\
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M %%%% !1110 4444 %9GB/\ Y%?5_P#KRF_] -:=9GB/_D5]7_Z\IO\ T T
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M.@#S*O0_A-_R%-1_ZXK_ .A5YY7H?PF_Y"FH_P#7%?\ T*@#U:BBB@ HHHH
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M5)!_T&)/^_ _^*H_X5)!_P!!B3_OP/\ XJO2** /-_\ A4D'_08D_P"_ _\
MBJHZS\,1INCW5[;Z@\\D"&3RS"!D#KSGTS7JU(ZJZ,C %6&"#W% 'S/6IX<U
M0Z-X@LK[)"1R 28_N'AOT)J/7--;1]<O+!LXAD(4GNO53^1%9] 'TP"& (((
M/0BEKF_ NJ_VKX4M69LRV_[B3ZKT_P#'<5TE !1110 4444 %%%% '.>.M-.
MI^$KQ%7,D($Z?5>3_P".[A7A-?3#*'4JP!4C!![U\]^(M*;1=>N[ @[(W)C)
M[H>5_0T 1:)J3:1K=G?KG]S(&8#NO1A^1-?1$<B31))&P9'4,K#H0>AKYHKV
M'X:Z\-0T8Z9,^;BS&%SU:+M^73\J .XHHHH **** "BBB@ HHHH **** "BB
MB@#B?BA?BV\,I:!OGNIE4CU5?F/ZA?SKQRNO^(VLC4_$C6\3;H+(>4,="_\
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MP^&9%4X\V14/TZ_TKRRO6RJC'E=5[['C9K7ES*DMMPHHHKUSQPHHHH ****
M"BBB@ HHHH **** +6GZA<Z9>)<VLA21?R8>A]17L&D:G%J^F0WD7 <?,O\
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M_'_)J /2**** "BBB@ HHHH **** "O,_BY_S!_^V_\ [3KTRO,_BY_S!_\
MMO\ ^TZ /,J]#^$W_(4U'_KBO_H5>>5Z'\)O^0IJ/_7%?_0J /5J*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\O\ BMJNZ>STE&X0>?(/
M<\+^F[\Z]/9@BEF("@9)/:OGG7]3.L:]>7Y)VRR'9GL@X7] * ,VNZ^%^E_:
M]?EU!U_=V<?RG_;;('Z;OTKA:]P^'VE?V9X4MW9<2W1,[Y]#]W_QT _C0!U-
M%%% !1110 4444 %%%% !1110!Y7\5M*\N]L]51?EF7R9#_M#E?S&?\ OFO.
MJ][\8Z5_:_A>\@5=TJ+YL7KN7G'XC(_&O!* .]^%NJ_9M9GTUV^2Z3<@_P!M
M>?Y9_*O7*^<--OI-,U.VO8OOP2*X'K@]/QZ5]%V\\=U;17$3;HY4#H?4$9%
M$E%%% !1110 4444 %>?_$_03=Z?%K$"9EMODFQU,9/!_ _S/I7H%,EBCGA>
M*5 \;J596&00>"* /FFM#1=6N-#U:"_MS\T9^9<\.O=3]:N^+/#LOAS67M\,
M;63+V\A_B7T^HZ'\^]85 'T;I>IVVKZ=#?6C[HI5R/53W!]Q5RO"O"'BR?PU
M?$/NDL93^^B!Z?[2^_\ /\J]ML;^VU*SCN[.998)!E67^7L?:@"Q1110 444
M4 %%%% !1110 5SOC+Q&GA[17=&'VR<%+=??NWT'\\5HZUK=EH-@UW>R;5'"
M(/O.WH!ZUX5KNN77B#5)+VZ."?E2,'B->P'^>M &:S%F+,223DDGK0BL[JB*
M69C@ #DFDKO/AMX<-_J/]KW"?Z-:MB($??D_^MU^N* /1_#6D#0_#]I8X'F*
MNZ4CNYY/^'X5K444 %%%% !1110 4444 %%%% 'SSXC_ .1HU?\ Z_9O_0S6
M96GXC_Y&C5_^OV;_ -#-9E 'O'@7_D2],_W&_P#0VKH:Y[P+_P B7IG^XW_H
M;5T- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7.^.-+
M?5O"=Y#$NZ:,":,#J2O)Q[XS7145=.;A-370F45)-,^8J*]-\8?#F9[F74=#
M0.KDM):]"#W*>WM^7H/.+FTN;.0QW5O+ XX*R(5/ZU]70Q-.M&\&>/4I2INS
M(:***W,PHHHH **** "BBB@ HHHH **DAAEGD$<,3R.>BHI)/X"NX\+_  YO
M;ZXCN=8B:VLU.?);B23VQ_"/KS_.LJU>G1CS39<*<INT4=1\+],>S\.27<JE
M6O)=R@_W%X!_/=7<TR.-(8DBC0)&BA551@ #H!3Z^4K575J.;ZGL4X<D5$Q?
M%=@^H>';F*-29$ D4#N5Y(_+->0U[Q7!>)?!4KSO>Z4H8.=SV_0@^J_X5Z66
MXN-.].;LGL>7F>$E4M5@KM;G"45+/;3VLACN(9(G'\+J5/ZU%7NIIZH\%IK1
MA1110 4444 %%%% !1110 444^.*29PD4;.YZ*HR: &5Z9X!L'M=&DN9!@W+
MY4?[(X!_/-8.@^";N[F2?4HVM[8'/EMP[^V.P_6O2(T6*-8T4*B@*J@< #M7
MBYEBX2C[*#OW/:RW"3C+VLU;L.JCK-D=1T:[M%^])&0O^]U'Z@5>HKQHR<9*
M2Z'LRBI1<7U/"&4HQ5@0P."#VI*]%\4>#FOYGO\ 3@HG;F2$G <^H/8UP5S9
M75D^RZMY86]'0BOJ\/BJ=>-XO7L?*8C"U*$K26G<KT445T'.%%%% !1110 4
M444 %%%% !13E1G8*BEF/0 9-=)HG@R_U&59+N-[6UZDN,.P] /ZG]:SJUH4
MES3=C2E1G5ERP5S:^'=@R075^ZD"0B.,^H')_I^5=Q45M;16=M';P($BC7:J
MCL*EKY;$5O;57/N?58:C[&DH=@HHHK W"BBB@ HHHH **** "BBB@#R3XK_\
MAZR_Z]?_ &9JX&N^^*__ "'K+_KU_P#9FK@: /3?A'_S&/\ MA_[4KTRO /#
M_BC4/#?VC["L!^T;=_FJ3]W.,<C^\:V_^%H>(/[EE_WZ/_Q5 'LE%>-_\+0\
M0?W++_OT?_BJ/^%H>(/[EE_WZ/\ \50![)17C?\ PM#Q!_<LO^_1_P#BJ/\
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M7EU>H_"3_CUU7_?C_DU 'I%%%% !1110 4444 %%%% !7F?Q<_Y@_P#VW_\
M:=>F5YG\7/\ F#_]M_\ VG0!YE7H?PF_Y"FH_P#7%?\ T*O/*U]!\1WWAR>:
M:Q$):50K>:I/ .?44 ?05%>-_P#"T/$']RR_[]'_ .*H_P"%H>(/[EE_WZ/_
M ,50![)17C?_  M#Q!_<LO\ OT?_ (JC_A:'B#^Y9?\ ?H__ !5 'LE%>-_\
M+0\0?W++_OT?_BJ/^%H>(/[EE_WZ/_Q5 'LE%>-_\+0\0?W++_OT?_BJ/^%H
M>(/[EE_WZ/\ \50![)17C?\ PM#Q!_<LO^_1_P#BJ/\ A:'B#^Y9?]^C_P#%
M4 >R45YIX4\>:QK7B6TT^Z6U$,N_=LC(/",PYSZ@5Z70 4444 %%%% !1110
M!S'C[5?[+\*7.UL37/[A/^!?>_\ '<_I7AM=W\4=5^U:[#IZ-F.TCRP_VVY_
MEM_,UPE %_1-.;5]:L[!<_OI0K$=0O5C^ !-?1"(L<:QHH5% "@=@*\K^%6E
M>;?W>J.ORPKY49/]YN3^0'_CU>K4 %%%% !1110 4444 %%%% !1110 5\_^
M*M*_L?Q+>VBKMBW[XO\ <;D?EG'X5] 5YK\5M*W1V6K(O*DP2GV/*_\ LWYB
M@#S"O9_AKJOV_P ,BU=LRV3^6?78>5/\Q^%>,5U_PXU7^S_%"6[MB*\7RCGI
MNZJ?SX_&@#VJBBB@ HHHH **** "BBB@#)\0Z#;>(M+>SN/E;[T4H',;=C]/
M45X5JVDWFBZA)97L>R5.A[,.Q![BOHNL?Q%X;LO$ECY%T-DJ9,4RCYHS_4>H
MH ^?JU] \2ZCX=NO-LY<QL?WD+\H_P"'8^XI->\.:AX>NS#>1?NR?W<R\HX]
MCZ^U9- 'N6@^.](UM4C:46EV>L,QQD_[+=#_ #]JZ>OF:MO3/%NN:0H2UU"3
MRATBDPZX] #T_#% 'OU%>46OQ8OT4"[TVWF([QN8\_GNK23XLV9'SZ5.#[2@
M_P!* /1:*\YD^+5J%_=Z3,Q]&E _H:S+OXKZC("+33[:#/>1C(1_*@#UDG R
M:X_Q#\0M+TA7ALV6^NQQMC/R*?\ :;^@_2O+-4\3ZSK(*WM_*\9_Y9J=J?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MSP;_ ,B?I?\ UQ'\S4?_  @OAK_H%1_]]O\ XUMVEI!8VD=K;1B.&,;40$G
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MT >6_#[_ )'G3O\ MK_Z*>O<ZQK'PIH>FWD=W9Z>D5Q'G:X9CC((/4^A-;-
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M87BGQ+;^&M,,[@27,F5@AS]X^I]AWH T-3U>PT:U-Q?W*0Q]LGECZ =2?I7
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MGAW_ )YW/_?XT <S_P +9OO^@9;?]]M7I&CWS:GHUG?.@1IXED*@\#(KG?\
MA6GAW_GG<_\ ?XUU%E9Q:?8P6< (BA0(@)R<"@"Q1110 5YMK'Q+O-,UF\L4
MT^!U@E:,,7.3@UZ37S]XK_Y&S5?^OI_YT >\V%P;S3K6Y90K31)(0.V0#5BJ
M.B?\@'3O^O6+_P!!%7J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BO/OB=JNH:9_97V&\FMO,\W?Y3E=V-F,_F?SJQ\--3O
MM3TZ^>^NYKADE4*96+8&* .YHHHH **** $)"@DD #J37F%]\5IEOW6QL(7M
M5;"M*QW./7CI^M>GLH=2K#((P17D%_\ ##6(]09+%H)K5F^21Y-I4?[0]?IF
M@#T[0M9@U[2(=0@5D$F0R-R48<$>]:59'AG0U\/:)#8"02."7D<# 9CUQ[=!
M^%:] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 56O;"UU&W,%W DL9[-V]P>U6:*:;3NA-)JS./G^'FG/(6ANKB)3_"<-CZ
M<5'_ ,*YM/\ G_G_ .^!7:45U+'8A?:.5X'#O[)Q?_"N;3_G_G_[X%'_  KF
MT_Y_Y_\ O@5VE%/Z_B/YOR%]0PW\OYG%_P#"N;3_ )_Y_P#O@4?\*YM/^?\
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M )Z,!\P'U'/X>]>J5Y1H_P /?$&F:S9WP>SQ!,KL!*<D \CIW&:]7H ****
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MZ&E=A\2_^1/D_P"NT?\ .N/^%7_(T7/_ %Y-_P"AI0![!1110 4444 %%%%
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MX,?:[";K@Y4-_1A^= 'T'17!^$/B"FK31Z?J@2*\8[8Y5X64^A'8_H?:N\H
M**** "BBL+QE_P B?JG_ %Q/\Q0!NT5XC\/+B*U\4?:)W$<45M([L>@ '-2>
M)?'&I:]=-;6+RV]D3M2*/AY/]XCU]!Q]: /7;C6-,M'*7.HVD+#@B2=5/ZFI
M[:ZM[R'S;6XBGCSC?$X8?F*\(@\&^(KE-\>DW !_O@(?R;%>I?#[3KS2_#CV
M][;O!-]H9MCCG!"\T =71110 445P_B_Q_'HTKZ?IJI->KQ([<I%[>Y_E^E
M';DA02Q  ZDU2;6=+5B&U*S!'4&=?\:\)EN]<\37FQY+J^F/(C7+!?HHX K2
MB^'WB:5-W]G!!C@/,@)_#- 'ML%S;W*[K>>*5?6-PP_2I:^?[W0->T!A<7%G
M<VVT\31G(4_[RG _.NH\*_$:ZMYX[/6I#/;L0HN#]^/W;U'Z_6@#UBBD!#*&
M4@@C(([TM !1110 45F>(_\ D5]7_P"O*;_T UXWX%_Y'33/]]O_ $!J /=Z
MAN+NVM%#7-Q%"#WD<+_.N#\;^/)-.N'TO267[0O$UQU\L_W5]_4]OKTX2U\.
M^(M?)NH[*YN-_/G3-C=_P)B,T >XIJ^FRN$CU"T=CT"S*2?UJY7@USX'\2VL
M1DDTJ4J/^>;+(?R4DTS1O%6L^'IPL,[F)#AK:;)3Z8/0_3% 'OE%8WASQ'9^
M)+#[1;?)*F!-"Q^:,_U![&MF@ HHHH **** "F2S1P)OED2-/[SL *\_\7?$
M3[%-)I^C%'G0E9+DC(0]PH[GWZ5Y]'!K?B:[9U2[OYN['+!?Q/ H ]V&M:42
M -3LR3V\]?\ &KB.LB!T8,IY!!R#7AI\ >*%7<=+.,9XFC)_+=5".XUWPO=@
M*UW82YSL8%0WX'AA0!]!T5Q'A#Q]%K4BV&HA(+X\(R\)+_@WMW[>E=O0 444
M4 %%%<S\0?\ D1M1_P"V7_HU* .FHKQ;X:?\CA'_ -<9/Y5[30 4444 %%<5
M\4/^133_ *^D_DU<]\)O^0IJ/_7%?_0J /5J*** "BBO+?B#X>U?5/$BW%C8
M33Q"W5=Z#C()X_6@";XN?\P?_MO_ .TZL_";_D%ZC_UV7_T&O-]1T;4=(\O^
MT+22W\W.S>/O8QG^8IVG:'J>K1O)864MPB'#%!T- 'T317@?_"&^(O\ H$7/
MY"O=+!&CT^VC<%66)00>Q % %BBBB@ HHKP/QE_R.&J?]=C_ "% 'OE%4=$_
MY .G?]>L7_H(J]0 4444 %%%<-XP\?QZ/(^GZ:$FOEXD=N4B/I[M^@_2@#MW
MD2)"\CJBCJS' %4_[:TH'!U.RS_UW7_&O"'FUOQ->X9KJ_G/.T L%^@'"C\A
M6B/ 'BAEW#2SC&>9HP?RW4 >XQ31SIOBD21/[R,"*?7SW);ZWX9NPSI=V$W9
MAE0WT(X-=_X1^(AO)X]/UG:LSD+'<J,!CZ,.Q]QQ]* /1:*** "BBB@ HJKJ
M.H6VE6$U[=R!(8ERQ[GT ]STKQSQ#X^U7697BMI7L[/.%CB.&8?[3#G\!Q0!
M[)/J%E:MMN+RWA;TDE5?YFFQ:KIT[[(;^UD<]%292?T->(V/@OQ%J48FBTZ0
M(W.Z9@F??#$&I+KP%XEM8C(VFM(HZ^4ZN?R!R: /=:*\)T/Q?K'AVY$?F22V
MZG#VLQ.!],\J:]HTC5K76]-BOK1\QN.0>JGN#[B@"]1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>$]-N&)+&$(Q/<J2I/Z4 ;5%%% !7C?Q0_Y&Q/\ KU3^;5[)7C?Q0_Y&Q/\
MKU3^;4 =]\/O^1&T[_MK_P"C7KIJYGX??\B-IW_;7_T:]=-0 4444 <?\2_^
M1/D_Z[1_SKC_ (5?\C1<_P#7DW_H:5V'Q+_Y$^3_ *[1_P ZX_X5?\C1<_\
M7DW_ *&E 'L%%%% !1110 4444 %%%% !1110 4444 5=2_Y!=W_ -<7_P#0
M37S]HG_(>T[_ *^HO_0A7T#J7_(+N_\ KB__ *":^?M$_P"0]IW_ %]1?^A"
M@#Z+HHHH **** "BBB@ KY^\5_\ (V:K_P!?3_SKZ!KY^\5_\C9JO_7T_P#.
M@#K/ 7A1-8)UK5E,T(;;#&_(<KQD^H&, >WM7J@ 50J@  8 ':LSPW;I:^&=
M,A3H+9#]25!)_,FM2@ KEO&?A2#7M-DGAB"ZC"I:-U',F/X#ZY[>A_&NIHH
M^>_#FJ/HWB"SO0VU$D"R^Z'AOTKZ$KYVUZ)8/$.IPQC"1W<JJ/8.17T#8.9-
M.MG;[S1*3^0H L4444 %<IX]\1-H6B".W<K>7>4C8=47^)OU 'U]JZNO$_B-
MJ#7OBZ>+.8[5%A7ZXR?U)_*@"KX1\+R^)M3979DLX<-/(.O/11[GGZ5[;8V%
MKIMHEK9P)#"G14'ZGU/O6-X'TM=+\*6:XQ).OGR''4MR/R&!^%=%0 55U#3K
M35+-[6]@2:%^JL.GN#V/O5JB@#P3Q7X<E\,ZOY&YGMY!O@E/4CT/N/\  ]Z]
M5\#>(&U_05,[;KNV/E3$]6]&_$?J#57XE:>EYX4DN<#S+219%/?!.TC]0?PK
MCOA;>F#Q++:D_)<0'C_:4@C]-WYT >PT444 %87C+_D3]4_ZXG^8K=K"\9?\
MB?JG_7$_S% 'A-LL\LRV]ON,DY$05>K9(P/SQ7N'A7PC9^';-&,:2W[+^]G(
MR0?1?0?SKR_X?P)/XTL X!";WQ[A#C]<'\*]SH **** "BBB@"KJ9O!IES_9
MZJUWY9$(<X&[L:\4MO!NN7>O16-Y:SP-,Y:2=UW*!U9MW0G\>IKW6B@#/TC1
MK'0[%;2QA"(/O-_$Y]6/<UH444 -=%D1D=0R,,%6&017B7CWP_%H.N@VJ[;2
MZ4R1K_<.?F4>W?\ &O;Z\Q^+4\#-I< =3.GF,5!Y53MZ_7'Z4 =#\.=3?4/"
MD:2MN>UD,&3W4 %?T./PKK:\\^$W_(+U'_KLO_H->AT %%%% &9XC_Y%?5_^
MO*;_ - ->#:3J4ND:E%?0J&EB#;,] 2I /X9S7O/B/\ Y%?5_P#KRF_] -?/
M]G;/>7L%K']^:18U^I.!_.@#T/P!X1COU_MW54\X,Y,$<G(<YY=O7GI^?I7J
M &!@5#:6T5G:0VL*[8H4"(/0 8%34 %<IXR\'V^OV<EQ;QJFI1KE' QYF/X6
M]?8]JZNB@#Y_\.:U/X<UZ*Y^945O+N(_[R9Y&/4=?J*]^CD26-)(V#(X#*P[
M@UXG\0],73O%D[(N([I1./J<AOU!/XUZ1X OC?>#[/<<O!N@/_ 3Q_XZ10!T
MU%%% !7'?$/Q&VC:.MI;/MN[S*AAU1/XC]><#\?2NQKPSQ]J#:AXON^<I;X@
M0>FWK_X\6H =X+\*-XDOV>?<EA 096'!8]E']?0?45[5:6=M86R6UI"D,*#"
MH@P!67X1TI-(\,V5N%Q(R"64^KL,G\N!^%;= !5/4]+LM8LWM;Z!98F]>JGU
M![&KE% '@/B70;CPQK1MR[&/_66\PX++G@_45Z[X-U\^(- CGE(^TQ'RI_=@
M/O?B,'ZYK)^)^G+<^&EO-O[RTE!W?[+?*1^>W\JYSX4WK1ZU>61/R30;\?[2
MD?T8T >M4444 %<S\0?^1&U'_ME_Z-2NFKF?B#_R(VH_]LO_ $:E 'GGPT_Y
M'"/_ *XR?RKVFO%OAI_R.$?_ %QD_E7M- !1110!Q7Q0_P"133_KZ3^35SWP
MF_Y"FH_]<5_]"KH?BA_R*:?]?2?R:N>^$W_(4U'_ *XK_P"A4 >K4444 %%%
M% 'F?Q<_Y@__ &W_ /:=6?A-_P @O4?^NR_^@U6^+G_,'_[;_P#M.K/PF_Y!
M>H_]=E_]!H ]#HHHH **** "O _&7_(X:I_UV/\ (5[Y7@?C+_D<-4_Z['^0
MH ]NT3_D Z=_UZQ?^@BKU4=$_P"0#IW_ %ZQ?^@BKU !1110!S7C?Q"?#^A,
MT+8O+@^7#_L^K?@/U(KR;PSX?N/$VLBV#,L0_>3S==J_XGM6Q\3=0-WXI^RA
MOW=I$J8[;F&XG\B!^%=O\.-+6P\+1W)4":\8RL>^T<*/RY_&@#HM+TJRT>S6
MUL8%BB'7'5CZD]S5VBB@"O>V5MJ-I):W<*302##(PR/_ *Q]Z\,\6^''\-ZP
M;=6+VT@WP.>I7T/N*][K)USPYIWB%(4OT=O))*%&VD9QG^0H S? 6MOK7AN,
MSN6N;9O)D8GEL#@_E^H-=161H7AK3_#HG%@)0)]I<.^[IG&/SK7H **** /,
M?BQJ$@DL-.4D1[3.X_O'.%_+YOSH^&/AVWFADUJZC$CI)Y=N&'"X'+?7G ],
M&HOBS:2"^T^\P3&T;1$^A!S_ %_2K'PQ\0VL=K)HMS(L<QD,D!8X#Y RH]^,
M^^: /2Z*** .$^(GA5-0L6U:SA_TV''F*B\RITZ=R/Y9]JI?#6PUS3;FX6ZL
M9H=/G3=F4;2''0A3SR,]NPKTBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHIDTJ00R32-M2-2S'T Y-&X;$-]J%KIML;B\F6*
M,<9/4GT ZDUR5S\1;9)"+;3Y)4'\3R!,_A@UQ^N:Q/K6HO<RDB,<11YX1?\
M'UK-KW\/E=-1O5U9\_B,TJ.5J6B.\_X63_U"?_)G_P"QH_X63_U"?_)G_P"Q
MK@Z*Z/[.PW\OXO\ S.?^T<3_ #?@O\CO/^%D_P#4)_\ )G_[&C_A9/\ U"?_
M "9_^QK@Z*/[.PW\OXO_ ##^T<3_ #?@O\CO/^%D_P#4)_\ )G_[&C_A9/\
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M>J?S:O9*\;^*'_(V)_UZI_-J .^^'W_(C:=_VU_]&O735S/P^_Y$;3O^VO\
MZ->NFH **** ./\ B7_R)\G_ %VC_G7'_"K_ )&BY_Z\F_\ 0TKL/B7_ ,B?
M)_UVC_G7'_"K_D:+G_KR;_T-* /8**** "BBB@ HHHH **** "BBB@ HHHH
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M3-.T/0KO2[2Y&C:<?-A23/V5.<J#Z5:_X1S0O^@+IW_@*G^% 'E/_"R_$?\
MSUM_^_(H_P"%E^(_^>MO_P!^17JW_".:%_T!=._\!4_PH_X1S0O^@+IW_@*G
M^% 'D&H>/=<U.PFLKF2 PS+M<+$ <?6CX>DCQQIV#U\W/_?MJ]?_ .$<T+_H
M"Z=_X"I_A4MOHNE6DZSVVF64,RYVR1P*K#(P<$#TH O4444 %87C+_D3]4_Z
MXG^8K=K"\9?\B?JG_7$_S% 'EWPY_P"1TM/]R3_T U[=7B/PY_Y'2T_W)/\
MT U[=0 4444 %%%% !63K/B72M!0&_N@LA&5B4;G;\!_,\5%XKUS_A'] FO5
M ,Q(CA!Z%STS] "?PKQ6RLM2\4:UY4;-/=SDN\CG@#N2>P__ %4 =S??%D9*
MZ?IA([/</C_QT?XUAW'Q,\13?ZM[:#_KG#G_ -")KK]*^&&DVJ*VHR2WDV/F
M 8H@/L!S^M=);^&=#M0/)TFS!'1C"K'\SS0!XV_BGQ1J;^6NHWDCG^&W&TG\
M$ JCJ>D:M9117FIV\T1N&(4SGYV(QG(//<=:^A(XHX4V1HJ+Z*,"O.OBV?\
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M30 4444 <5\4/^133_KZ3^35SWPF_P"0IJ/_ %Q7_P!"KH/BDP7PI&">6ND
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?*\#\9?\CAJG_78_R% 'MVB?\@'3O^O6+_T$5>JCHG_(!T[_ *]8O_015Z@
MHHHH \C^*>F-!K5OJ*K^[N8]C'_;7_ZQ'Y&MWX7ZTMSI,NDR-^^M6+Q@GK&Q
MYQ]#G\Q74^)-#B\0Z+-8R$*Y^>)_[CCH?Z'V->'12ZEX8US<H:WO;5\%2./<
M'U!'Y@T ?0]%<OX?\<Z3K<*)),EI>8^:&5L G_9)X/\ .NG!! (.0>A% "UR
MGC+Q@WAC[+'#!'/-/N8J[$;5&.>/4_R-7=<\7Z1H4+&:Y2:XQ\MO$P9B??\
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M"9%)[,O(Q^(_6O(_!#O'XSTPIG)D*GZ%2#^E='X[\<6^I6K:3I3EX&(\^?&
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MV'JW_0+O?_ =_P#"C^P]6_Z!=[_X#O\ X5[311_:\_Y4']D0_F9XM_8>K?\
M0+O?_ =_\*/[#U;_ *!=[_X#O_A7M-%']KS_ )4']D0_F9XM_8>K?] N]_\
M =_\*/[#U;_H%WO_ (#O_A7M-%']KS_E0?V1#^9GBW]AZM_T"[W_ ,!W_P *
M/[#U;_H%WO\ X#O_ (5[311_:\_Y4']D0_F9XPF@ZN[!1I=YD^L+ ?F172:)
MX#N))5FU4B*(<^2K99OJ1T'Z_2O0Z*SJYI5FK15C2EE5&#O)W&QQI%&L<:A4
M4850, "G445YAZ84444 %%%% !1110 4444 %%%% !1110!AZ_X4TOQ$F;N(
MI< 86>/AQ['U'UKSC4_ACK5H[&R:&]B[;6"/^(/'ZU['10!X _A'Q#&Q4Z/=
MDC^[&6'YBGP>#/$=P^U-)N%/_30!!^;$5[Y10!Y7H_PKN9'635[I(8^IB@^9
MC[%CP/UKTC3=+LM(LUM;&W2&(=EZL?4GJ35RB@ HHHH **** "F2Q1SQ/%*B
MR1N-K(PR"/0BGT4 >:Z_\+A)(]QHDRIGDVTQ.!_NM_0_G7&7'@_Q%9O\^DW1
M(/!A7S/_ $'->^T4 ?/P\.>(KEPITG421T\R%P/S(K?TCX9:O>2*VH,EE!W!
M8.Y'L!P/Q/X5[%10!GZ/HMCH5B+2QBV)U9CRSGU)[UH444 %%%% !7F_CKPC
MK&N>(%N["W22$0*F3(J\@GL3[UZ110!A^$--N=)\+6=C>($N(M^Y0P.,NQ'(
M]B*W*** "BBB@#G?&VDWFM>''L[&,23&5&"E@O Z\FN<\!>$]7T'79[K4+=(
MXGMFC!$BM\Q93V/H#7HM% !1110 4444 %%%% !1110 4444 %%%% $%[&TU
MC<1(,N\3*H]R*\BTSX?^(K;5K.>6TC$<4Z.Q\Y3@!@3WKV2B@ HHHH ****
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MB@ HHHH *RO$EE/J/AR^L[90T\L6U%) R?J:U:* /,/!G@S6]'\36][>VR)
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH S/$?_ "*^K_\ 7E-_Z :\6\&_\CAI?_78?R->X:K:/?Z/>V<;*KW%O)$K
M-T!92!G\ZX'0?AQJ.DZ[9W\MY:O'!)O94W9/TXH ]*HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
-HH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>lctx-20250127.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-01-27T12:54:16.2075+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://lineagecell.com/20250127" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:lctx="http://lineagecell.com/20250127" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://lineagecell.com/20250127/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://lineagecell.com/20250127/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="lctx-20250127.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://lineagecell.com/20250127/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46183713517216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Jan. 27, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan. 27,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Lineage Cell Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000876343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-12830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3127919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2173 Salk Avenue, Suite 200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Carlsbad<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(442)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">287-8990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common shares<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LCTX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MIR1-\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%
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MR3J)T]UY<:*X+XGVZLN[D K=,+?S+$M5 ]ZD*VHAR*2FZ U+&W=9:B,8FQH
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M8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ PX,[6IE<G",0!@  G"<  !,
M             ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M" ##@SM:E$T7&U($  "2$   &               @($-"   >&PO=V]R:W-H
M965T<R]S:&5E=#$N>&UL4$L! A0#%     @ PX,[6I^@&_"Q @  X@P   T
M             ( !E0P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " ##@SM:
MEXJ[',     3 @  "P              @ %Q#P  7W)E;',O+G)E;'-02P$"
M% ,4    " ##@SM:.JJBYT !   \ @  #P              @ %:$   >&PO
M=V]R:V)O;VLN>&UL4$L! A0#%     @ PX,[6B0>FZ*M    ^ $  !H
M         ( !QQ$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#
M%     @ PX,[6F60>9(9 0  SP,  !,              ( !K!(  %M#;VYT
D96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  ]A,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="lctx-20250127.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lineagecell.com/20250127/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="lctx-20250127.htm">lctx-20250127.htm</File>
    <File>lctx-20250127.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "lctx-20250127.htm": {
   "nsprefix": "lctx",
   "nsuri": "http://lineagecell.com/20250127",
   "dts": {
    "inline": {
     "local": [
      "lctx-20250127.htm"
     ]
    },
    "schema": {
     "local": [
      "lctx-20250127.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://lineagecell.com/20250127/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_000a1c80-a808-446b-84e2-9057827f4e98",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lctx-20250127.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_000a1c80-a808-446b-84e2-9057827f4e98",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lctx-20250127.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://lineagecell.com/20250127/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://lineagecell.com/20250127/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://lineagecell.com/20250127/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://lineagecell.com/20250127/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://lineagecell.com/20250127/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://lineagecell.com/20250127/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://lineagecell.com/20250127/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://lineagecell.com/20250127/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://lineagecell.com/20250127/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://lineagecell.com/20250127/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://lineagecell.com/20250127/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://lineagecell.com/20250127/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://lineagecell.com/20250127/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://lineagecell.com/20250127/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://lineagecell.com/20250127/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://lineagecell.com/20250127/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://lineagecell.com/20250127/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://lineagecell.com/20250127/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://lineagecell.com/20250127/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://lineagecell.com/20250127/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://lineagecell.com/20250127/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://lineagecell.com/20250127/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0000950170-25-009227-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-009227-xbrl.zip
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M<;UM>VDP>?^7M^U!.8S?_S]02P,$%     @ PX,[6C*D>9=I"   2ET  !$
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M(_'KN\&=X+> S_\'4$L! A0#%     @ PX,[6L@A 635&P  S?<  !$
M         ( !     &QC='@M,C R-3 Q,C<N:'1M4$L! A0#%     @ PX,[
M6C*D>9=I"   2ET  !$              ( !!!P  &QC='@M,C R-3 Q,C<N
9>'-D4$L%!@     "  ( ?@   )PD      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>lctx-20250127_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="lctx-20250127.xsd" xlink:type="simple"/>
    <context id="C_000a1c80-a808-446b-84e2-9057827f4e98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000876343</identifier>
        </entity>
        <period>
            <startDate>2025-01-27</startDate>
            <endDate>2025-01-27</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="C_000a1c80-a808-446b-84e2-9057827f4e98"
      id="F_00731e60-6969-45d2-b21c-f9c8515ca503">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_000a1c80-a808-446b-84e2-9057827f4e98"
      id="F_1511b0e0-be9d-4105-98a8-ce8a53903ae1">0000876343</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="C_000a1c80-a808-446b-84e2-9057827f4e98"
      id="F_e2cdc7d0-99d8-4e41-9246-0cf306c0a534">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_000a1c80-a808-446b-84e2-9057827f4e98"
      id="F_c1d3fc7a-01a1-4e51-9885-3376d7852ec9">2025-01-27</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_000a1c80-a808-446b-84e2-9057827f4e98"
      id="F_bdd069ce-eb00-478d-b110-0c0e4c42da11">Lineage Cell Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_000a1c80-a808-446b-84e2-9057827f4e98"
      id="F_42546a62-bb9c-47a9-99aa-d569989f5ace">CA</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_000a1c80-a808-446b-84e2-9057827f4e98"
      id="F_dd646a90-5184-4142-9928-165003f79cc8">001-12830</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_000a1c80-a808-446b-84e2-9057827f4e98"
      id="F_a815a7da-502d-48bd-a888-5848518fbdc3">94-3127919</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_000a1c80-a808-446b-84e2-9057827f4e98"
      id="F_a089bc55-c72e-4a72-aac7-3bdc9b83205d">2173 Salk Avenue, Suite 200</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_000a1c80-a808-446b-84e2-9057827f4e98"
      id="F_9d08df4b-be4d-43f5-90df-ee15c895dc87">Carlsbad</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_000a1c80-a808-446b-84e2-9057827f4e98"
      id="F_83451471-53d6-4b35-931c-8dbe992ebdcc">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_000a1c80-a808-446b-84e2-9057827f4e98"
      id="F_baa5bd89-0faf-4e0f-af32-0a286589fe51">92008</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_000a1c80-a808-446b-84e2-9057827f4e98"
      id="F_e2bd2a59-dc1e-49b2-a21a-848302ddbd56">(442)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_000a1c80-a808-446b-84e2-9057827f4e98"
      id="F_037f4153-962b-42bf-8351-395e61f76bcc">287-8990</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_000a1c80-a808-446b-84e2-9057827f4e98"
      id="F_be7233e3-48e6-4e96-b30d-888c6f33106c">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_000a1c80-a808-446b-84e2-9057827f4e98"
      id="F_05a5f538-fb19-4d4f-ac6f-3a3523ab6cd4">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_000a1c80-a808-446b-84e2-9057827f4e98"
      id="F_e48a216c-bb7d-4302-a72e-92b84f7297f9">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_000a1c80-a808-446b-84e2-9057827f4e98"
      id="F_f9867ecd-1cda-4a7a-b8a0-099a79a0be9d">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_000a1c80-a808-446b-84e2-9057827f4e98"
      id="F_809a53cb-dcef-40d9-83ee-6a394a975b8b">Common shares</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_000a1c80-a808-446b-84e2-9057827f4e98"
      id="F_371a4c04-2b21-481e-93bc-e0feb11499ba">LCTX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_000a1c80-a808-446b-84e2-9057827f4e98"
      id="F_b2dba600-ad30-4ffa-83da-2b8001ce5898">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_000a1c80-a808-446b-84e2-9057827f4e98"
      id="F_61e8b6f9-827d-4d25-bdbc-7d6341a1c7c1">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
